Form 4: GlycoMimetics Director Acquires Shares in Lieu of Fees
SEC Form 4
Mark Alan Goldberg, a director at GlycoMimetics, acquired 4,584 shares of common stock in lieu of board and committee retainer fees.
Summary
- On March 29, 2024, Mark Alan Goldberg, a director of GlycoMimetics Inc. (GLYC), acquired 4,584 shares of common stock.
- The acquisition was made in lieu of $13,750 in board and committee retainer fees, as per the issuer's non-employee director compensation policy.
- Following the transaction, Goldberg directly owns 24,828 shares and indirectly owns 11,497 shares through family trusts.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects a standard compensation practice. The director taking shares instead of cash could be seen as a slightly positive signal.
Positives
- The director's decision to take shares in lieu of cash may signal confidence in the company's future prospects.
Industry Context
Directors often receive equity as part of their compensation, aligning their interests with those of shareholders. This is a common practice in the biotech industry.
Stakeholder Impact
- The transaction has a minor positive impact on shareholders as it aligns the director's interests with theirs.
Key Dates
| Date | Description |
|---|---|
| 03/29/2024 | Date of transaction: Mark Alan Goldberg acquired shares of common stock. |
| 04/01/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.